FMP

FMP

Enter

AGRX - Agile Therapeutics, ...

photo-url-https://images.financialmodelingprep.com/symbol/AGRX.png

Agile Therapeutics, Inc.

AGRX

NASDAQ

Inactive Equity

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

1.51 USD

0.05 (3.31%)

AGRX Financial Statements

Year

2023

2022

2021

2020

Total Revenue

19.59M

10.88M

4.1M

749k

Cost of Revenue

8.98M

6.84M

10.72M

282k

Gross Profit

10.62M

4.05M

-6.62M

467k

Operating Expenses

30.5M

45.48M

64.39M

49.52M

Research and Development

2.23M

3.25M

6.25M

13.5M

Selling, General & Administrative Expenses

28.27M

42.23M

58.14M

36.02M

Selling & Marketing Expenses

17.77M

30.37M

43.44M

23.29M

General & Administrative Expenses

10.51M

11.86M

14.7M

12.73M

Other Expenses

0

4.29M

-5.3M

0

Operating Income

-19.88M

-41.43M

-71M

-49.05M

Total Other Income/Expenses Net

5.42M

11.35M

-62k

-2.8M

Income Before Tax

-14.46M

-30.09M

-74.89M

-51.85M

Income Tax

1.42M

-4.67M

1.69M

2.83M

Net Income

-14.46M

-25.41M

-76.58M

-54.69M

Basic EPS

-6.71

-58.79

-63.12k

-1.29k

EPS Diluted

-6.71

-58.79

-63.12k

-1.29k

Basic Average Shares

2.16M

432.22k

1.21k

42.34k

Diluted Average Shares

2.16M

432.22k

1.21k

42.34k

EBITDA

-19.88M

-39.9M

-64.93M

-48.47M

Retained Earning Schedule

Year

2023

2022

2021

2020

Retained Earnings (Previous Year)

-408.7M

-387.12M

-312.22M

-260.37M

Net Income

-14.46M

-25.41M

-76.58M

-54.69M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-423.17M

-408.7M

-387.12M

-312.22M

Other Distributions

-14.47M

-21.59M

-74.89M

-51.85M

PPE Schedule

Year

2023

2022

2021

2020

Gross PPE

487k

872k

13.4M

14.38M

Annual Depreciation

386k

1.53M

2.22M

276k

Capital Expenditure

0

-133k

-269k

-353k

Net PPE

101k

-529k

11.44M

14.46M

Intangible and Goodwill Schedule

Year

2023

2022

2021

2020

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep